April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” T cells with memory features grow in number and gather around hair follicles when there are not enough immune cells.
September 2024 in “Journal of the American Academy of Dermatology” Regulatory γδ T cells help protect hair follicles from alopecia areata and promote hair regrowth.
CD28 is a promising target for treating alopecia areata with belatacept.
CD28 is a promising target for treating alopecia areata with belatacept.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
9 citations
,
March 2017 in “Journal of Visualized Experiments” The assay effectively identifies compounds that affect immune cell activation.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking CCR5 can prevent and improve hair loss in alopecia areata.
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
1 citations
,
December 2022 in “Frontiers in Immunology” Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.
9 citations
,
May 2005 in “Expert Review of Clinical Immunology” Blocking interferon-gamma might help treat various autoimmune diseases.
54 citations
,
August 1981 in “British Journal of Dermatology” Alopecia areata is linked to reduced T cell function and auto-immunity.
71 citations
,
May 2019 in “Rheumatology” Tph cells are linked to the severity of systemic lupus erythematosus.
20 citations
,
November 2019 in “Current Opinion in Systems Biology” The document concludes that computational models are useful for understanding immune responses and could improve cancer immunotherapy.
6 citations
,
November 2018 in “American journal of transplantation” UV light helped human hair transplants survive in mice without broad immunosuppression.
17 citations
,
January 2010 in “PubMed” CD10 helps distinguish between basal cell carcinoma and benign hair follicle tumors.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
21 citations
,
December 2005 in “The journal of investigative dermatology/Journal of investigative dermatology” T-cells in alopecia areata scalp show abnormal regulation, leading to less inflammation.
July 2017 in “Cancer Research” Krt15+ cells in mice can resist radiation, regenerate tissue, and start tumors, suggesting new cancer treatment targets.
7 citations
,
February 2015 in “Journal of comparative pathology” CD8+ T cells play a key role in graft-versus-host disease in certain mice models.
7 citations
,
December 2016 in “Journal of the American Academy of Dermatology” NKG2D+CD4+ T cells are higher in alopecia areata patients and may be involved in the disease.
September 2020 in “Benha Journal of Applied Sciences” Higher IL-19 levels are linked to more severe Alopecia Areata.
5 citations
,
November 2005 in “Journal of Investigative Dermatology” 69 citations
,
February 2008 in “The American journal of pathology” Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.
March 2016 in “Benha Veterinary Medical Journal” Type XIX Collagen is present in specific skin and hair cells during development.
March 2026 in “Skin Appendage Disorders” Belatacept may be a promising treatment for alopecia areata.
21 citations
,
April 2019 in “Journal of cutaneous pathology” People with alopecia areata have fewer regulatory T-cells than those with other skin conditions.
June 2021 in “Working paper of public health” Six months after COVID-19, most patients still had autoantibodies.
January 2024 in “Wiadomości Lekarskie” Enhancing immune response can improve cancer treatment effectiveness.
11 citations
,
May 2023 in “Journal of Cancer Research and Clinical Oncology” CRISPR/Cas systems show promise for cancer treatment by targeting miRNAs, but delivery and specificity challenges remain.